



Title	Post-irradiation changes and dose determinations in thorium-impregnated liver and spleen a case report
Author(s)	Watanabe, Noritoshi; Mandai, Tatsuo; Russell, J. Walter et al.
Citation	日本医学放射線学会雑誌. 1964, 24(5), p. 493-501
Version Type	VoR
URL	<a href="https://hdl.handle.net/11094/14733">https://hdl.handle.net/11094/14733</a>
rights	
Note	

*The University of Osaka Institutional Knowledge Archive : OUKA*

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

# POST-IRRADIATION CHANGES AND DOSE DETERMINATIONS IN THORIUM-IMPREGNATED LIVER AND SPLEEN A CASE REPORT

Noritoshi Watanabe, M.D.<sup>1\*</sup>

Tatsuo Mandai, B.S.<sup>2\*\*</sup>

Walter J. Russell, M.D.<sup>1\*\*\*</sup>

Haruma Yoshinaga, Ph.D.<sup>3\*\*\*\*</sup>

Department of Radiology<sup>1</sup> and Radioisotope Laboratory<sup>2</sup>, Atomic Bomb Casualty  
Commission and Research Institute for Nuclear Medicine  
and Biology<sup>3</sup>, Hiroshima University, Hiroshima, Japan

ATOMIC BOMB CASUALTY COMMISSION

Hiroshima and Nagasaki Japan

A Cooperative Research Agency of

U.S.A. NATIONAL ACADEMY OF SCIENCES-NATIONAL  
RESEARCH COUNCIL

and

JAPANESE NATIONAL INSTITUTE OF HEALTH OF THE MINISTRY  
OF HEALTH AND WELFARE

With funds provided by

U.S.A. ATOMIC ENERGY COMMISSION

JAPANESE NATIONAL INSTITUTE OF HEALTH

U.S.A. PUBLIC HEALTH SERVICE

肝臓および脾臓のトリウム沈着による照射後変化および線量測定

(症例1)

渡 辺 哲 敏 万 代 達 男

Walter J. Russell 吉 永 春 馬

(昭和39年7月3日受付)

二酸化トリウム使用の歴史を簡単に総括した。  
組織内におけるトリウム沈着値の推定および線量  
計算に当つて遭遇した若干の困難について述べる  
とともに、22年前のトロトラスト静注患者の組織  
を用いて実施した化学検査、X線写真およびオー

トラジオグラフィによる研究成果を合わせ紹介し  
た。この患者においては肝臓および脾臓の推定被  
照射線量はそれぞれ 680 rem および 25000 rem  
であつた。

Present address: \*Radiology Department, Faculty, of Medicine, Tokyo University, Tokyo, Japan  
\*\*Radioisotope Laboratory, Atomic Bomb Casualty Commission, Hiroshima, Japan  
\*\*\*Chief, Radiology Department, Atomic Bomb Casualty Commission, Hiroshima,  
Japan  
\*\*\*\*Professor, Department of Experimental Radiology, Faculty of Medicine, Kyushu  
University, Fukuoka, Japan

## BACKGROUND

The early use of thorium and other radioisotope materials in medicine and industry has been reviewed by Looney<sup>1</sup>. Thorium was first applied clinically in 1928<sup>2,3</sup> to visualize the liver and spleen radiographically and gradually became more widely used for this purpose<sup>4,5</sup> and as a contrast medium for bronchography, carotid angiography and cerebral angiography.<sup>1</sup> It was also used to visualize genitourinary structures,<sup>6</sup> in placentography, mammography and in angiography of the extremities.<sup>1</sup> Its usefulness in detecting accessory spleens was also reported.<sup>7</sup> Due to its ability to concentrate mainly in the histiocytic elements of the liver and spleen, its greatest value continued to be in hepatolienography.

Earlier analyses of cases in which thorium was administered failed to produce convincing evidence of early or late damage attributable to it.<sup>8,9</sup> Immediate or early histological changes attributed to thorotrast were reported in laboratory studies by Wen<sup>10</sup> and Pohle<sup>11</sup> in 1933 and 1934. Thorotrast is a colloidal suspension containing 20 per cent thorium dioxide and 20 per cent dextran with 0.15 per cent methyl-p-hydrobenzoate as a preservative.<sup>12</sup>

Thorium is radioactive with a half life of  $1.4 \times 10^{10}$  years. Most of its effect is caused by alpha radiation (90 per cent), with a small contribution by beta (10 per cent) and gamma rays (1 per cent).<sup>13</sup> Early investigations showed that the majority of the material intravenously administered to laboratory animals and patients was immediately deposited in the liver and spleen and that only very small amounts were excreted.<sup>14</sup> Because of its radioactivity and its prolonged retention, early warnings of possible late effects were issued<sup>14,15,16</sup> and in 1932 the Council on Pharmacy and Chemistry of the American Medical Association refused to endorse it for intravenous use.<sup>12</sup> Some who used it clinically suggested it be restricted to patients in older age groups, with serious disease, and with a short life expectancy.<sup>11,17,5</sup> In 1947, MacMahon<sup>18</sup> reported the first neoplasm in a patient attributable to the use of thorotrast, and subsequently an additional number of neoplasms of wide variety have been documented. They were summarized by Baserga<sup>19</sup>. (Figure 1)

Neoplasms were produced in laboratory animals<sup>20</sup> by thorotrast injections in 1949. Additional neoplasms of the renal pelvis,<sup>21</sup> liver<sup>19</sup> and other sites have been reported. Amory<sup>22</sup> and others have pointed out that severe and often incapacitating fibrotic changes occur at the sites of intravenous administration of thorotrast, particularly if there is extravasation. It has been emphasized that the fibrotic changes which result from its administration are due to the radiation, rather than a nonspecific reaction.<sup>23</sup> Cases of aplastic anemia have also been attributed to thorotrast administration.<sup>24,25</sup> Dahlgren<sup>13</sup> and others have pointed out the importance of documenting all cases of thorotrast administration, and that all such cases should be given periodic follow-up examinations in an attempt to detect more cases of neoplasia.

Immediately following the injection of thorotrast the deposit of the compound has been reported to be 50 per cent<sup>15</sup> and 60 per cent<sup>26</sup> in the liver and 10 per cent<sup>15,26</sup> in the spleen. Deposit in the liver 5 years after injection was reported 27 per cent by Jacobson and Rosenbaum.<sup>27</sup> Okinaka<sup>28</sup> reported a deposit of 18.7 per cent in the liver and 25.8 per cent

Figure 1 Malignant Tumors in Man Attributed to Injection of Thorotrast<sup>10</sup>

Type tumor	P. age, yr.	Pt. sex	Latent period, yr.	Amount & route injection	Reference
Endothelial cell sarc. liver	70	F	12	75 ml. intravenous	MacMahon et al.
Spindle cell sarc. kidney	64	M	16	30 ml. retrograde pyelography	Zollinger
Carc. breast	47	M	12	? intraductal	Austoni
Carc. eyelid	51	M	35	? in lacrimal duct	Rudolphi
Squam. cell carc. maxillary sinus	64	F	10	? into maxillary sinus	Hofer
Bronchogenic carc.	47	M	18	? bronchography	Vogtlin & Minder
Endothelial cell sarc. liver	...	F	3	20 ml. intra-arterial	Horta
Hemangioendothelioma liver	63	F	14	24 ml. intra-arterial	Ludin
Carc. extrahepatic biliary ducts	39	M	22	? intravenous	Heitmann
Carc. liver	53	F	21	80 ml. intravenous	Matthes
Sarc. at site injection	54	F	6	20 ml. arteriography	Plenge & Kruckemeyer
Carc. maxillary sinus	36	M	15	? into maxillary sinus	Gros et al.
Hemangioendothelioma liver	49	M	12	? intra-arterial	Fruhling et al.
Malig. peritoneal "thorotrastoma"	60	F	17	24 ml. intraperitoneal	Scheibe
Hemangioendothelioma liver	54	M	14	? intra-arterial	Tesluk & Nordin
Carc. kidney	75	M	?	? ?	Boemke
Cholangiocarc. liver	54	M	21	? intra-arterial	Grossiord et al.
Bronchogenic carc.	75	M	16	? ?	Hackenthal
Angioblastic sarc. liver	46	M	22	? intra-arterial	Horta
Cholangiocarc. liver	52	F	21	70 ml. intravenous	Matthes
Carc. extrahepatic biliary ducts	45	F	17	? intra-arterial	Roberts & Carlson
Carc. liver	58	M	12	? intra-arterial	Batzenschlager & Wilhelm
Carc. breast	43	F	17	? intraductal	Brody & Cullen
Carc. liver	37	M	13	? intra-arterial	Federlin & Scior
Carc. ovary	45	F	23	? salpingography	Schwenzer & Federlin
Bronchogenic carc.	38	M	13	? bronchography	Roth
Carc. pancreas & kidney	70	M	13	? intra-arterial	Wuketich & Mark
Endothelial cell sarc. liver	61	M	24	75 ml. intravenous	Grampa & TommasiniDegna
Carc. liver	48	F	24	? intravenous	Morgan et al.
Adenocarc. lung	43	M	24	? intravenous	Nielsen & Kracht
Mixed tumor kidney	66	F	?	? ?	Nielsen & Kracht
Carc. seminal vesicle	68	M	14	? urethrovesicography	Gelzer & Scheidegger
Carc. liver & lung	57	M	19	? intra-arterial	Werthemann
Hemangionsarc. liver	50	M	13	80 ml. intra-arterial	Rosenbaum
Giant follic. lymphoma spleen	65	F	15	15 ml. intra-arterial	Gardner & Ogilvie
Carc. left hepatic duct	47	F	24	? intra-arterial	Gardner & Ogilvie

in the spleen 11 years after injection. Shimanouchi<sup>29</sup> reported 11.3 per cent deposit in the liver and 1.35 per cent in the spleen 17 years after injection.


In calculating dose to the tissues, the distribution of the thorium, the distribution and excretion of thorium daughters formed in the body, the excretion of thorium as a function of time following injection and the self-absorption of particle energy within the deposits of thorium must be considered.<sup>30</sup> A large number of small deposits of thorium in an organ may be expected to give a relatively uniform dose to the organ; larger aggregates may contribute a nonuniform dose, and there may be self-absorption within them.<sup>30</sup> Therefore doses vary widely within an organ and among organs of different cases.<sup>30</sup>

Quantitative autoradiography, radiochemical and spectrochemical procedures should be employed in dose determinations where possible. Hursh et al.<sup>31</sup> calculated that an individual who received 15gm. of thorium in 75 ml. of thorium dioxide received the following doses per week: Liver, 1.5 rad; spleen, 2.5 rad; bone marrow, 0.3 rad. Rotblat and Ward<sup>30</sup> presented the following doses per week of a patient who received 22 ml. of thorium dioxide intravenously: Spleen, interior 4.8 rep; spleen, exterior 8.3 rep; spleen, hilum, 3.5 rep; and liver, 8.1 rep. Rundo<sup>32</sup> calculated cumulative dose in rep to the liver, spleen and bone marrow for a standard man following the injection of 20 ml. of thorotrast, as shown in Figure 2. Figure 3 illustrates the decay of thorium.

Figure 2 Cumulative Dose (Rep) to Liver, Spleen, and Bone Marrow for a Standard Man After Intravenous Administration of 20 ml. Thorotrast<sup>32</sup>

Organ	Weight	Th. content	After 5 years		After 10 years		After 20 years	
			Alpha	Beta	Alpha	Beta	Alpha	Beta
Liver	1700	70% 2.8gm.	109	7.3	316	16	726	42
			61	2.7	189	11	695	36
Spleen	150	25% 1 gm.	310	25	580	56	1320	149
			117	9	354	38	1100	130
Bone marrow	1500	5% 0.2gm.	6.3	0.5	12	1.1	27	3.0
			2.4	0.2	7	0.6	22	2.6

Figure 3 Decay of Thorium



## CASE REPORT

A 46 year old Japanese male received thorotrast intravenously for purposes of visualizing the liver, 22 years previously. Clinical information concerning the patient's earlier history and physical findings was lost during the confusion of World War II. It is not possible to reconstruct the patient's history accurately, but it is known that he had a

cholecystomy in 1938, in Manchuria. The administration of thorotrast presumably took place just before this surgery. The amount administered is not known.

On January 5, 1960, a Hiroshima hospital diagnosed the patient as having liver disease on the basis of physical findings, but he refused hospitalization. Clinically, a neoplasm secondary to thorotrast administration was suspected.<sup>33</sup> He developed jaundice and malaise 2 days later. When finally hospitalized 4 months later he was found to be anemic (RBC 2,090,000/mm<sup>3</sup>; Hgb 8.5 gm per cent) and had a moderate leukocytosis (WBC 14,200) and ascites. Liver function studies were abnormal; icterus index was 120; van den Bergh: direct, 4+; indirect, 4+. Paracentesis was performed and 800 cc. whole blood transfused during that admission. He expired June 29, 1960.

An autopsy (#60-AH-118) was performed at the Atomic Bomb Casualty Commission (ABCC), Department of Pathology. Gross findings included absence of the gallbladder, stenosis of the orifice of the common bile duct, dilatation of hepatic ducts, moderate biliary cirrhosis, 3,500 cc. ascitic fluid and esophageal varices with hemorrhage. Histological findings included chronic passive congestion of the spleen, with hemorrhage, fibrosis, hemosiderosis and extensive thorium deposits in the stroma of axillary and inguinal lymph nodes. Sections of the stomach and ileum showed chronic inflammatory changes. The liver showed extensive secondary biliary cirrhosis, proliferation of bile ducts, regeneration of liver, and deposition of thorium mainly in Kupffer cells. Bone marrow of the sternum and rib cage showed deposition of thorium and fibrotic changes. There was moderate cholemic nephrosis involving both kidneys. The formalin-fixed tissues were analyzed 6 months after death.

### ANALYSIS OF TISSUE

#### Radiography

Sections of the formalin-fixed liver and spleen 1.5 cm. in thickness each were used to make the roentgenograms shown in Figure 4. These roentgenograms were made using 58 kilovolts, 5 milliamperes seconds, and employing the usual processing techniques.




Figure 4(a)




Figure 4(b)

Radiographs of sections of (a) liver and (b) spleen, showing aggregates of thorotrast in tissue, and fibrotic change secondary to the thorotrast. (Five times)

There is a relative increase in the amount of dense tissue in the affected liver and spleen, representing fibrosis. The histological findings at autopsy confirmed the presence of such fibrotic change.

#### Autoradiography

Sections of the liver and spleen  $5\mu$  in thickness were used for autoradiographic analysis, employing a Kodak-nuclear  $5\mu$  emulsion, using the stripping method. Numerous alpha tracks were visualized on the emulsion, and are shown in Figure 5. Fibrotic changes in the connective tissue are also visible. Also seen are large numbers of small aggregates of approximately  $5\mu$  in diameter each and a very small number of large aggregates of thorotrast.




Figure 5 (a)




Figure 5 (b)

Autoradiographs of the (a) liver and (b) spleen showing numerous alpha tracks in tissue.

#### Chemical Analysis and Dosimetry

The method used was that described by Ishibashi and Azuma<sup>34</sup> in which ashed samples of the organs were acidified and dissolved and the thorium was precipitated by centrifugation. The precipitate was analyzed by colorimetric method. In our study, the wet liver specimen weighed 1,670 gm. and the wet spleen specimen weighed 55 gm.

By chemical analysis calculations showed a deposition of 0.37 mg. of thorium per gram of liver and 13.7 mg. of thorium per gram of spleen. The total thorium in the liver was 0.62 gm., while that in the spleen was 0.75 gm. The amount of thorium in the liver was calculated to be  $0.068 \mu\text{c}$ , while that in the spleen was  $0.082 \mu\text{c}$ , according to the following formula.

Formula:

$$C = (K) \frac{(W)}{(A) \cdot (T)}$$

$C$  = activity in curies  
 $W$  = radioisotope weight in grams  
 $K = \text{constant} = \frac{6.02 \times 10^{23}}{3.7 \times 10^{10} \times 1.44}$   
 $A$  = mass number  
 $T$  = half-life in seconds

By knowing the effective absorptive energy for the organ of reference, in terms of thorium and its daughters (Fig. 3), the dose to each organ was calculated according to the following formula :

$$R \text{ (rem)} = \frac{(\text{disintegrations/sec}/\mu\text{c})(\text{effective energy})(\mu\text{c thorium per organ})(\text{time in sec})(\text{erg/MEV})}{100 \times \text{organ weight in grams}}$$

According to International Committee for Radiation Protection (ICRP),<sup>35</sup> effective energy is expressed as  $\Sigma EF \text{ (RBE)}n$ . Here it is assumed to be the same for liver and spleen, and the values for these organs is expressed as 41, according to ICRP.

The time, 22 years, expressed as seconds is  $6.9 \times 10^8$ .

Making appropriate substitutions in the formula, the dose for the case in this report was calculated as follows :

(a) Liver

$$R \text{ (rem)} = (3.7 \times 10^4) \times 41 \times \frac{0.068}{1670} \times 6.9 \times 10^8 \times \frac{1.6 \times 10^{-6}}{100} = 68 \times 10^1$$

$$R \text{ (rem)} = 680$$

(b) Spleen

$$R \text{ (rem)} = (3.7 \times 10^4) \times 41 \times \frac{0.082}{55} \times 6.9 \times 10^8 \times \frac{1.6 \times 10^{-6}}{100} = 25 \times 10^3$$

$$R \text{ (rem)} = 25,000$$

Dose to the liver was 680 rem ; that to the spleen was 25,000 rem.

#### Scintillation Counter Study

Using a thorium standard of 8.41 gm., wet samples of liver (0.45 gm.) and spleen (0.42 gm.) were counted in a well scintillation counter. It will be noted from Table I that the total volumes of thorium in the liver and spleen were estimated to be 0.58 and 0.76 gm. respectively by use of the scintillation counter. The results obtained by chemical analysis and scintillation counting are shown in Table I.

Table I

Sample	Weight (gm.)	Scintillation Counting Method			Chemical Method	
		C/M	Net C/M	Total Thorium per organ (gm)	Total Thorium per organ(gm)	Total Thorium in $\mu\text{c}$
Patient's Liver	1670	236	35	0.58	0.62	0.068
Patient's Spleen	55	1498	1297	0.76	0.75	0.082
Normal Liver	—	201	—	—	—	—
Normal Spleen	—	197	—	—	—	—
Th-St 8.41mg.	—	2107	1892	—	—	—
Background	—	202.4	—	—	—	—

In this counting procedure, it is difficult to estimate the radioactivity of daughters in organs which have been removed ; therefore, the values of scintillation counting were used only as a supplemental reference.

#### DISCUSSION

Calculation of dose to organs and tissues in which thorium dioxide has been deposited



is extremely difficult. A small amount of the thorium and its daughters are excreted from the body; self absorption of alpha particles occurs in the aggregates of thorium in the tissues; and there are difficulties in studying thorium distribution in tissues. Dose estimates have a wide variation, and the factor may be as low as 2 or as high as 20 within an organ.

In spite of the difficulties encountered in determining the amount of thorium dioxide in the tissue, and in the calculation of dose to the tissue impregnated, a reasonable estimate can be made by chemical analysis of the tissue, by quantitative autoradiographic examination and making appropriate calculations. Even though there is a likelihood of significant error in these methods, it is still very useful to make these determinations.

### SUMMARY

A brief review of the history of the use of thorium dioxide is presented. Some of the difficulties encountered in estimating amounts of thorium in impregnated tissue, and making dose calculations are cited. Results of chemical analysis, radiographic and autoradiographic studies of tissues of a patient who received intravenous injection of thorotrast 22 years previously are also presented. Estimates of dose to the liver and spleen of this individual were, 680 rem and 25, 000 rem respectively.

### ACKNOWLEDGEMENTS

Appreciation is extended to Dr. Mutsuaki Shinagawa, Department of Chemistry, Hiroshima University, for his consultation and advice concerning the method of chemical analysis of tissue.

### References

- 1) Looney, W.B.: Initial medical and industrial use of radioactive materials; 1915—1940 *Am. J. Roentgenol., Rad. Therapy & Nuclear Med.*, 1954, 72, 838—848. —2) Oka, M.: Eine neue Methode zur roentgenologischen Darstellung der Milz (Lienographie). *Fortschr. Roentgenstr.*, 1929, 40, 497—501. —3) Radt, P.: Eine neue Methode zur roentgenologischen Sichtbarmachung von Leber und Milz durch Injektion eines Kontrastmittels (Hepato-Lienographie). *Med. Klin.*, 1930, 26, 1888—1891. —4) Erickson, L.G., and Rigler, L.G.: Roentgen visualization of liver and spleen with thorium dioxide sol with particular reference to preoperative diagnosis of carcinomatous metastases to liver. *J.A.M.A.*, 1933, 100, 1758—1764. —5) Rigler, L.G., Koucky, R.F., and Abraham, A.L.: Effects of thorium dioxide sol (thorotrast) on human liver. *Radiology*, 1935, 25, 521—532. —6) Ritter, J.S., and Rattner, I.N.: Umbrathor in urography. *Am. J. Roentgenol. and Rad. Therapy*, 1932, 28, 629—633. —7) Loeb, V., Seaman, W.B., and Moore, C.V.: The use of thorium dioxide sol (thorotrast) in the roentgenologic demonstration of accessory spleens. *Blood*, 1952, 7, 904—914. —8) Yater, W.M., and Coe, F.O.: Ten years' experience with thorotrast hepatosplenography. *Ann. Intern. Med.*, 1943, 18, 350—366. —9) Cassel, C., Ruffin, J.M., Reeves, R.J., and Stoddard, L.D.: Late effects of thorium dioxide in man. *Arch. Intern. Med.*, 1951, 88, 42—50. —10) Wen, I.C., and Jung, T.S.: Changes in tissues after intravenous injection of colloidal thorium dioxide. *Proc. Soc. Exp. Biol. Med.*, 1933, 31, 330—332. —11) Pohle, E.A., and Ritchie, G.: Histological studies of liver, spleen and bone marrow in rabbits following intravenous injection of thorium dioxide. *Am. J. Roentgenol. & Rad. Therapy*, 1934, 31, 512—519. —12) Council on pharmacy and chemistry. Thorotrast (preliminary report). *J.A.M.A.* 1932, 99, 2183—2185. —13) Dahlgren, S.: Thorotrast tumors. A review of the literature and report of two cases. *Acta Path. Microbiol. Scand.*, 1961, 53, 147—161. —14) Stewart, W.H., and Ghiselin, F.H.: Potential dangers of thorotrast as contrast agent in roentgen diagnosis; collective review. *Int. Abstr. Surg.*, 1938, 66, 395—397. —15) Taft, R.B.: Demonstration of gamma radiation from living patient following thorotrast injection. *Radiology*, 1937, 29, 530—532. —16)

- Prezyna, A.P., Ayres, W.W., and Mulry, W.C.: Late effect of thorotrast in tissues. *Radiology*, 1953, 60, 573—578. —17) Wachsmuth, W.: Investigation on damaging effects exerted by thorotrast on body tissues. *J.A.M.A. (abstracts)*, 1949, 140, 571—572. —18) MacMahon, H.E., Murphy, A.S., and Bates, M.I.: Sarcoma of liver; disadvantages of thorotrast as diagnostic agent. *Rev. Gastroenterol.*, 1947, 14, 155—159. —19) Baserga, R., Yokoo, H., and Henegar, G.C.: Thorotrast-induced cancer in man. *Cancer*, 1960, 13, 1021—1031. —20) Bauer, K.H.: Thorotrast: lesions caused by it and danger of development of sarcoma. *J.A.M.A. (abstracts)*, 1949, 140, 571—572. —21) Kruchemeyer, K., Lessmann, H.D., and Pudwitz, K.R.: Nierenkarzinom als Thorotrastschaden. *Fortschr. Roentgenstr.*, 1960, 93, 313—321. —22) Amory, H.I., and Bunch, R.F.: Perivascular injection of thorotrast and its sequelae. *Radiology*, 1948, 51, 831—839. —23) Thomas, S.F., Henry, G.W., and Kaplan, H.S.: Hepatolienography: past, present, and future. *Radiology*, 1951, 57, 669—684. —24) Spier, J., Cluff, L.E., and Urry, W.D.: Aplastic anemia following administration of thorotrast. *J. Lab. Clin. Med.*, 1947, 32, 147—154. —25) Duane, G.W.: Aplastic anemia 14 years following administration of thorotrast. *Amer. J. Med.*, 1957, 23, 499—501. —26) Adachi, T.: Experimentelle Untersuchungen über Thorotrast als Mikroradioaktive Substanz. *Nippon Acta Radiol.*, 1940, 17, 289—339. —27) Jacobson, L.E., and Rosenbaum, D.: Postmortem findings and radio-activity determinations 5 years after injection of thorotrast. *Radiology*, 1958, 31, 601—607. —28) Okinaka, S., Nakao, K., Ibayashi, H., Nakaidzumi, M., Kakehi, H., and Sugimura, T.: A case report on the development of biliary tract cancer eleven years after injection of thorotrast. *Am. J. Roentgenol., Rad. Therapy & Nuclear Med.*, 1957, 78, 812—818. —29) Shimanouchi, T., Shionoya, T., Suwa, N., and Yokoyama, Y.: A case report of post-mortem findings and radioactivity determination 18 years after injection of thorium dioxide-sol in liver and spleen-with pearl tumor of cerebellopontile angle. *Nisshin-Igaku*, 1949, 36, 506—511. —30) Rotblat, J., and Ward, G.B.: Tissue dosage from thorotrast in the body. *Nature*, 1953, 172, 769—770. —31) Hursh, J.B., Steadman, L.T., Looney, W.B., and Colodzin, M.: The excretion of thorium and thorium daughters after thorotrast administration. *Acta radiol.*, 1957, 47, 481—498. —32) Rundo, J.: The radioactivity of thorotrast. *Phys. Med. Biol.*, 1956, 1, 138—146. —33) Mandai, T., and Watanabe, N.: A case of a long period retention of thorium dioxide. *Nippon Acta Radiol.*, 1961, 21, 218. —34) Ishibashi, M., and Azuma, S.: Determination of  $\mu\text{g}$  amount of thorium. *Japan Analyst*, 1955, 4, 14—16. —35) International Commission of Radiological Protection. Report of committee II on permissible dose for internal radiation. Pergamon Press, New York, 1959.